The Department of Health – Abu Dhabi (DoH) has sealed a Memorandum of Understanding (MoU) with Boehringer Ingelheim(BI), a leading research-driven pharmaceutical company, to advance scientific research and innovation.
Announced during BIO International Convention in Boston at the Abu Dhabi Pavilion, the MoU was signed by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI.
The signing ceremony was held in the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI
The agreement aims to foster groundbreaking research and development – to develop a thriving environment of scientific excellence. This strategic move will reinforce the emirate’s position as the MENA region’s premier hub for healthcare, life sciences and innovation.
The partnership enables researchers, scientists and innovators across Abu Dhabi to leverage the advanced data and resources of Boehringer Ingelheim’s OpnME platform, aimed at addressing critical biological challenges and accelerating scientific discovery.
Dr. Asma Al Mannaei Executive Director of the Health Life Sciences Sector – DoH
“Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as part of our efforts to advance health outcomes and improve the quality of life for communities around the world. We’re empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers’ rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.”
Through four flagship programs, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent.
OpnME platform connects forward-thinking researchers to drive transformative, research-driven medical innovation for generations to come.
“At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration supports research, innovation, and the next generation of researchers in the region,” added Ousama Alhaj.
